tbuckley/cabot-search huggingface dataset:
Assessment of Duplicate Publication of Chinese-Sponsored Randomized Clinical Trials
Authors: Yuanxi Jia, Doudou Huang, Jiajun Wen, Riaz Qureshi, Yehua Wang, Lori Rosman, Qingkun Chen, Karen A. Robinson, Joel J. Gagnier, Stephan Ehrhardt, David D. Celentano
Journal: JAMA Network Open (2020)

Duplicate publications of randomized clinical trials are prevalent in the health-related literature. To date, few studies have assessed the interaction between duplicate publication and the language of the original publication.To assess the existence of duplicate publication and the extent to which duplicate publication is associated with the language of the original publication.In this retrospective cohort study, eligible randomized clinical trials were retrieved from trial registries, and bibliographic databases were searched to determine their publication status. Eligible randomized clinical trials were for drug interventions from January 1, 2008, to December 31, 2014. The search and analysis were conducted from March 1 to August 31, 2019. The trial registries were either primary registries recognized by the World Health Organization or the Drug Clinical Trial Registry Platform sponsored by the China Food and Drug Administration.Individual randomized clinical trials with positive vs negative results.Journal articles were classified as main articles (determined by largest sample size and longest follow-up among all journal articles derived from that randomized clinical trial) and duplicates. The duplicates were classified into 4 types: (1) unreferenced subgroup analysis (article did not disclose itself as a subgroup analysis or reference its main article); (2) unreferenced republication (article did not disclose itself as a replicate of the main article or reference it); (3) unreferenced interim analysis (article did not disclose itself as an interim analysis or reference its main article); and (4) partial duplicate (article did not disclose its sharing a subset of participants with other articles or reference them).Among 470 randomized clinical trials published by August 2019 as journal articles, 55 (11.7%) had 75 duplicates, of which 53 (70.7%) were cross-language duplicates. Of the 75 duplicates, 33 (44.0%) were unreferenced republications, 25 (33.3%) unreferenced subgroup analyses, 15 (20.0%) unreferenced interim analyses, and 2 (2.7%) partial duplicates. When the main article of a randomized clinical trial was published in Chinese, those with positive findings were 2.48 (95% CI, 1.08-5.71) times more likely to have subsequent duplicate publication than those with negative findings.In this study, most duplicates were cross-language duplicates and the most common type was unreferenced republication of the main article. Duplicate publication bias exists when the main articles of randomized clinical trials were published in Chinese, potentially misleading readers and compromising journals and evidence synthesis.
siRNA directed against EGFR has comparable efficacy to a first generation antisense oligonucleotide in combination therapy against the PC-3 prostate tumor line
Authors: Marvin Rubenstein, Paulus Tsui, Michael Ting, Kenneth Ting, Patrick Guinan
Journal: Cancer Research (2005)

569  Antisense oligonucleotides (oligos), directed against a variety of specific proteins, are well described specific agents for treating experimental prostate tumor models. In an effort to enhance their efficacy, we have administered them in combination with several traditional chemotherapeutic agents. In these inital studies, several combinations and sequences for administration were identified which demonstrated significant improvements in the inhibition of PC-3 prostate tumor cell growth. However, some investigators claim that oligo derivatives, such as siRNA, might have greater efficacy. To compare the effectiveness of siRNA to effective, but traditional, oligos, we compared their potency in similar combination therapy experiments using the PC-3 in vitro cell line. Two oligos were compared, both specific for the epidermal growth factor receptor (EGFR). The first was the previous described MR2 oligo (US patent # 5,610,288); the second an siRNA (also specifically directed against EGFR). Six comparative studies were conducted which included combination with the traditional chemotherapy agents Taxol, cisplatin and Cytoxan. PC-3 cells were seeded into microwell plates and allowed to adhere prior to the addition of agents. Cell numbers were determined following incubations using WST-1 uptake. When Taxol was administered in combination with either MR2 or siRNA, the MR2 was significantly more effective (p = 0.000277) against PC-3 cells incubated for 24 hrs in their presence. In a sequential study in which a 24 hrs Taxol treatment was followed with either MR2 or siRNA for an additional 24 hrs, no significant differences were found. When cisplatin was similarly administered in combination with either MR2 or the siRNA, no significant differences in inhibition were found. Furthermore, in the subsequent study in which a 24 hrs cisplatin treatment was followed with either MR2 or siRNA for an additional 24 hrs, again no significant differences were found. Lastly, in a series of sequential 24 hrs administrations including Cytoxan the following was found. PC-3 cells treated with Cytoxan, followed by either MR2 or siRNA produced similar inhibition, however the treatment with MR2 was significantly more inhibitory (p = 0.026095). When the cycle was reversed with MR2 or siRNA followed by Cytoxan, both treatments were again similarly inhibitory, but no significant differences were found between either oligo type. We conclude that although siRNA directed against EGFR has efficacy, and inhibited cell growth of the PC-3 line in group comparisons when: administered alone vs untreated controls; administered with Taxol vs Taxol alone; or administered with cisplatin vs cisplatin alone, it is not more effective than the better characterized MR2 oligo. Furthermore, we suspect that siRNA would provide no advantage in its ability to be specifically delivered.
Early versus delayed insulin pump therapy in children with newly diagnosed type 1 diabetes: results from the multicentre, prospective diabetes follow-up DPV registry
Authors: Clemens Kamrath, Sascha R Tittel, Thomas M Kapellen, Thekla von dem Berge, Bettina Heidtmann, Katrin Nagl, Ulrike Menzel, Simone Pötzsch, Katja Konrad, Reinhard W Holl
Journal: The Lancet Child & Adolescent Health (2020)
Abstract 11286: Spironolactone Lowers Loop Diuretic Requirements Without Adversely Affecting Renal Function and Electrolyte Balance in Patients With Heart Failure and Preserved Ejection Fraction: A TOPCAT Trial Analysis
Authors: Andreas P Kalogeropoulos, Jincy Thankachen, Javed Butler, James C Fang
Journal: Circulation (2018)

Introduction: In the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, spironolactone (SP) reduced risk for heart failure (HF) hospitalization amo...
If the Patient Is Frail, Emergency Abdominal Surgery Is High Risk
Authors: Hadiza S. Kazaure, Michael E. Lidsky, Sandhya A. Lagoo-Deenadayalan
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
&lt;xhtml:span xmlns:xhtml="http://www.w3.org/1999/xhtml" xml:lang="en"&gt;Association between SARS-CoV-2 infection and Kawasaki-like multisystem inflammatory syndrome: a retrospective matched case&amp;#8211;control study, Paris, France, April to May 2020&lt;/xhtml:span&gt;
Authors: Julie Toubiana, Corinne Levy, Slimane Allali, Camille Jung, Marianne Leruez-Ville, Emmanuelle Varon, Fanny Bajolle, Naim Ouldali, Judith Chareyre, Stephane Béchet, Annie Elbez, Jean-Laurent Casanova, Martin Chalumeau, Robert Cohen, Jérémie F Cohen
Journal: Eurosurveillance (2020)

We assessed the association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and Kawasaki disease (KD)-like multisystem inflammatory syndrome in a retrospective case-control study in France. RT-PCR and serological tests revealed SARS-CoV-2 infection in 17/23 cases vs 11/102 controls (matched odds ratio: 26.4; 95% confidence interval: 6.0-116.9), indicating strong association between SARS-CoV-2 infection and KD-like illness. Clinicians should keep a high level of suspicion for KD-like illness during the COVID-19 pandemic.
Current understanding of primary biliary cholangitis
Authors: Atsushi Tanaka
Journal: Clinical and Molecular Hepatology (2020)

Primary biliary cholangitis (PBC) causes chronic and persistent cholestasis in the liver, eventually resulting in cirrhosis and hepatic failure without appropriate treatment. PBC mainly develops in middle-aged women, but it is also common in young women and men. PBC is considered a model of autoimmune disease because of the presence of diseasespecific autoantibodies, that is, antimitochondrial antibodies (AMAs), intense infiltration of mononuclear cells into the bile ducts, and a high prevalence of autoimmune diseases such as comorbidities. Histologically, PBC is characterized by degeneration and necrosis of intrahepatic biliary epithelial cells surrounded by a dense infiltration of mononuclear cells, coined as chronic non-suppurative destructive cholangitis, which leads to destructive changes and the disappearance of small- or medium-sized bile ducts. Since 1990, early diagnosis with the detection of AMAs and introduction of ursodeoxycholic acid as first-line treatment has greatly altered the clinical course of PBC, and liver transplantation-free survival of patients with PBC is now comparable to that of the general population.
cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing
Authors: Carolina Uggenti, Alice Lepelley, Marine Depp, Andrew P. Badrock, Mathieu P. Rodero, Marie-Thérèse El-Daher, Gillian I. Rice, Somdutta Dhir, Ann P. Wheeler, Ashish Dhir, Waad Albawardi, Marie-Louise Frémond, Luis Seabra, Jennifer Doig, Natalie Blair, Maria José Martin-Niclos, Erika Della Mina, Alejandro Rubio-Roldán, Jose L. García-Pérez, Duncan Sproul, Jan Rehwinkel, Jonny Hertzog, Anne Boland-Auge, Robert Olaso, Jean-François Deleuze, Julien Baruteau, Karine Brochard, Jonathan Buckley, Vanessa Cavallera, Cristina Cereda, Liesbeth M. H. De Waele, Angus Dobbie, Diane Doummar, Frances Elmslie, Margarete Koch-Hogrebe, Ram Kumar, Kate Lamb, John H. Livingston, Anirban Majumdar, Charles Marques Lorenço, Simona Orcesi, Sylviane Peudenier, Kevin Rostasy, Caroline A. Salmon, Christiaan Scott, Davide Tonduti, Guy Touati, Marialuisa Valente, Hélio van der Linden, Hilde Van Esch, Marie Vermelle, Kate Webb, Andrew P. Jackson, Martin A. M. Reijns, Nick Gilbert, Yanick J. Crow
Journal: Nature Genetics (2020)
Targeting BMI-1-mediated epithelial–mesenchymal transition to inhibit colorectal cancer liver metastasis
Authors: Zhiyao Xu, Zhuha Zhou, Jing Zhang, Feichao Xuan, Mengjing Fan, Difan Zhou, Zhenyu Liuyang, Ximei Ma, Yiyang Hong, Yihong Wang, Sherven Sharma, Qinghua Dong, Guanyu Wang
Journal: Acta Pharmaceutica Sinica B (2020)

Liver is the most common metastatic site for colorectal cancer (CRC), there is no satisfied approach to treat CRC liver metastasis (CRCLM). Here, we investigated the role of a polycomb protein BMI-1 in CRCLM. Immunohistochemical analysis showed that BMI-1 expression in liver metastases was upregulated and associated with T4 stage, invasion depth and right-sided primary tumor. Knockdown BMI-1 in high metastatic HCT116 and LOVO cells repressed the migratory/invasive phenotype and reversed epithelial–mesenchymal transition (EMT), while BMI-1 overexpression in low metastatic Ls174T and DLD1 cells enhanced invasiveness and EMT. The effects of BMI-1 in CRC cells were related to upregulating snail via AKT/GSK-3β pathway. Furthermore, knockdown BMI-1 in HCT116 and LOVO cells reduced CRCLM using experimental liver metastasis mice model. Meanwhile, BMI-1 overexpression in Ls174T and DLD1 significantly increased CRCLM. Moreover, sodium butyrate, a histone deacetylase and BMI-1 inhibitor, reduced HCT116 and LOVO liver metastasis in immunodeficient mice. Our results suggest that BMI-1 is a major regulator of CRCLM and provide a potent molecular target for CRCLM treatment.
Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial
Authors: Mark Obermann, Steffen Nägel, Claudia Ose, Nilüfer Sonuc, André Scherag, Peter Storch, Charly Gaul, Andreas Böger, Torsten Kraya, Jan-Peter Jansen, Andreas Straube, Tobias Freilinger, Holger Kaube, Tim P Jürgens, Hans-Christoph Diener, Zaza Katsarava, Christoph Kleinschnitz, Dagny Holle
Journal: The Lancet Neurology (2020)
15524 Ten of TEN and counting: The story of Toxic Epidermal Necrolysis (TEN) at the University of New Mexico from 2017 to 2018
Authors: Mary E. Logue, Catherine N. Tchanque-Fossuo, Laura A. Valaas, Shelly Stepenaskie, Hillary Elwood, Emily M. Altman
Journal: Journal of the American Academy of Dermatology (2020)
Multimodality Quantitative Imaging of Aortic Root for Transcatheter Aortic Valve Implantation: More Complex Than It Appears**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: E. Murat Tuzcu, Samir R. Kapadia, Paul Schoenhagen
Journal: Journal of the American College of Cardiology (2010)
187P More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Authors: Q-Y. Chen, L-Q. Wang, Y-X. Gao, C-H. Zheng, P. Li, J-W. Xie, J-B. Wang, J-X. Lin, J. Lu, L-L. Cao, M. Lin, R-H. Tu, Z-N. Huang, J-L. Lin, H-L. Zheng, C. Huang
Journal: Annals of Oncology (2020)
Enhancing the Response to Cardiac Resynchronization Therapy: Is It Time to Individualize the Left Ventricular Pacing Site?**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: Jagmeet P. Singh, William T. Abraham
Journal: Journal of the American College of Cardiology (2010)
Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils
Authors: Michela Perego, Vladimir A. Tyurin, Yulia Y. Tyurina, Jonathan Yellets, Timothy Nacarelli, Cindy Lin, Yulia Nefedova, Andrew Kossenkov, Qin Liu, Sreesha Sreedhar, Harvey Pass, Johannes Roth, Thomas Vogl, David Feldser, Rugang Zhang, Valerian E. Kagan, Dmitry I. Gabrilovich
Journal: Science Translational Medicine (2020)

Tumor recurrence can be induced by stress-activated neutrophils via release of S100A8/A9 proteins and modified lipids.
Abstract S12-02: Risk of morbidity and mortality in COVID-19 patients with cancer
Authors: Naomi Alpert, Bridget Marcellino, Joseph Rapp, Wil Lieberman-Cribbin, Emanuela Taioli
Journal: Clinical Cancer Research (2020)

Abstract Introduction: Morbidity and mortality of cancer patients with COVID-19 have not been examined. The goal of this analysis was to compare the demographics and clinical characteristics of COVID-19 cancer patients to the rest of COVID-19 patients and assess whether cancer is associated with morbidity or mortality. Methods: COVID-19-positive patients with an inpatient or emergency encounter at the Mount Sinai Health System between 03/01/20-05/27/20 were included in the analysis. Patients were compared across cancer status (noncancer, non-solid cancers, and solid cancers) on demographics and clinical characteristics. Multivariable logistic regressions were used to model the associations of cancer status with sepsis, acute venous thromboembolism, and mortality. Results: There were 5,516 COVID-19 positive patients included, 96 (1.7%) with non-solid cancers and 325 (5.8%) with solid cancers. Those with solid cancers were significantly older (mean: 70.9 vs. 63.8 and 63.2 years) and more likely to be non-Hispanic Black (26.5% vs. 23.9% and 22.9%) than noncancer and non-solid cancers patients. Those with cancer had significantly more additional comorbid conditions (42.7% and 49.8% ≥2 comorbidities for non-solid and solid cancers, vs. 30.4% for noncancer). Platelets (mean [noncancer]: 223.8, mean [non-solid cancer]: 182.6, mean [solid cancer]: 218.3 × 103/μL), white blood cell count (mean [noncancer]: 8.4, mean [non-solid cancer]: 6.7, mean [solid cancer]: 8.0 × 103/μL), hemoglobin (mean [noncancer]: 13.1, mean [non-solid cancer]: 11.2, mean [solid cancer]: 12.0 g/dL), and red blood cell count (mean [non-cancer]: 4.5, mean [non-solid cancer]: 3.7, mean [solid cancer]: 4.1 × 106/μL) were significantly lower in cancer patients, and lowest in those with non-solid cancers. After adjustment and compared to noncancer patients, those with cancer had significantly higher risk of acute venous thromboembolism (ORadj: 1.77, 95% CI: 1.01-3.09) and sepsis (ORadj: 1.34, 95% CI: 1.09-1.64). There was no significant difference in mortality (ORadj: 1.02, 95% CI: 0.81-1.29). There was no significant difference in all outcomes for solid and non-solid cancer types. Conclusion: COVID-19 patients with cancer, particularly solid tumors, are significantly older, with more comorbidities than those without cancer. There was no statistically significant difference in mortality for COVID-19 patients with cancer, but a significantly higher risk of thromboembolism and sepsis. Further research into the effect that cancer treatments may have in inflammatory and immune responses to COVID is warranted. Citation Format: Naomi Alpert, Bridget Marcellino, Joseph Rapp, Wil Lieberman-Cribbin, Emanuela Taioli. Risk of morbidity and mortality in COVID-19 patients with cancer [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr S12-02.
A Patient Presenting With a Viral Prodrome, Palpitations, Dizziness, and Heart Block
Authors: Andrew E. Noll, Amila D. William, Niraj Varma
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Abstract 15779: Coronary Artery Calcium Score and Cardiovascular Events in Patients With Diabetes, Prediabetes, and No Diabetes: The Clarify Registry
Authors: Nour Tashtish, Sadeer Al-Kindi, Anuja Sarode, Jared Derieux, Robert Gilkeson, Sanjay Rajagopalan
Journal: Circulation (2019)

Introduction: Coronary artery calcium score (CACS) has been shown to improve prediction of cardiovascular events beyond probabilistic risk scores in asymptomatic individuals and is recommended by g...
Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders
Authors: Jie-Qiong Li, Yan-Lin Bi, Xue-Ning Shen, Hui-Fu Wang, Wei Xu, Chen-Chen Tan, Qiang Dong, Yan-Jiang Wang, Lan Tan, Jin-Tai Yu
Journal: Translational Neurodegeneration (2020)

Accumulating reports have suggested that α-synuclein is involved in the pathogenesis of Alzheimer's disease (AD). As the cerebrospinal fluid (CSF) α-synuclein has been suggested as a potential biomarker of AD, this study was set out to test whether CSF α-synuclein is associated with other AD biomarkers and could predict neurodegeneration and clinical progression in non-demented elders.The associations between CSF α-synuclein and other AD biomarkers were investigated at baseline in non-demented Chinese elders. The predictive values of CSF α-synuclein for longitudinal neuroimaging change and the conversion risk of non-demented elders were assessed using linear mixed effects models and multivariate Cox proportional hazard models, respectively, in the Alzheimer's disease Neuroimaging Initiative (ADNI) database.The CSF α-synuclein levels correlated with AD-specific biomarkers, CSF total tau and phosphorylated tau levels, in 651 Chinese Han participants (training set). These positive correlations were replicated in the ADNI database (validation set). Using a longitudinal cohort from ADNI, the CSF α-synuclein concentrations were found to increase with disease severity. The CSF α-synuclein had high diagnostic accuracy for AD based on the "ATN" (amyloid, tau, neurodegeneration) system (A + T+ versus A - T - control) (area under the receiver operating characteristic curve, 0.84). Moreover, CSF α-synuclein predicted longitudinal hippocampus atrophy and conversion from MCI to AD dementia.CSF α-synuclein is associated with CSF tau levels and could predict neurodegeneration and clinical progression in non-demented elders. This finding indicates that CSF α-synuclein is a potentially useful early biomarker for AD.
43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia
Authors: M. Md Yusof, D.W. Cescon, H.S. Rugo, S-A. Im, C. Gallardo, O. Lipatov, C.H. Barrios, E. Holgado, H. Iwata, N. Masuda, E. Gokmen, S. Loi, Z. Guo, E. Jensen, G. Aktan, V. Karantza, P. Schmid, J. Cortes
Journal: Annals of Oncology (2020)
106P Efficacy and tolerability of capecitabine and mitomycin-C based concurrent radiotherapy in patients with anal canal cancer
Authors: P.G. Bhargava, R. Engineer, A. Ramaswamy, S. Sujay Srinivas, M. Shah, A. Agarwal, A. Saklani, M. Parulekar, S. Mandavkar, V.S. Ostwal
Journal: Annals of Oncology (2020)